Simultaneous PD-1/VEGF/CTLA-4 blockade aims to compress multi-drug regimens into a single infusion, raising questions about ...

Alphamab Oncology (stock code: 9966.HK) announced that two latest clinical data on biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 for the treatment of primary platinum-refractory ...

Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) today announced the latest results from the ongoing Phase I/II CLINCH ...

TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in biomarker-unselected, heavily pre-treated PROC patients At data-cut-off on September ...

Climb Bio ( ($CLYM) ) has shared an announcement. Climb Bio, Inc. announced on October 17, 2025, the publication of new long-term follow-up ...

Incyte (INCY) announced the first clinical data evaluating its TGFbetaR2PD-1 bispecific antibody for patients with microsatellite stable, MSS, ...

Revolutionary AI assistant RISA eliminates the pain of hunting for patient data across multiple systems, enabling clinicians to focus more on patient ...

Lexeo Therapeutics Inc. (NASDAQ: LXEO) is one of the best young stocks with huge upside potential. On October 7, Lexeo ...

Stop to reveal the personal and professional drive behind a groundbreaking special issue of Prehospital Emergency Care ...

PluvictoTM plus standard of care (ARPI + ADT) significantly reduced risk of progression or death by 28% (HR 0.72) versus SoC alone, with positive trend in OS (HR 0.84) in PSMA+ metastatic ...